Trial Profile
A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Nov 2012
Price :
$35
*
At a glance
- Drugs Pridopidine (Primary)
- Indications Huntington's disease
- Focus Therapeutic Use
- 08 Nov 2012 New source identified and integrated (EudraCT2004-000394-60: European Clinical Trials Database).
- 05 Nov 2010 New trial record.